Ignite Creation Date:
2024-05-06 @ 1:16 PM
Last Modification Date:
2024-10-26 @ 1:11 PM
Study NCT ID:
NCT03975647
Status:
ACTIVE_NOT_RECRUITING
Last Update Posted:
2024-06-18
First Post:
2019-06-04
Brief Title:
A Study of Tucatinib vs Placebo in Combination With Ado-trastuzumab Emtansine T-DM1 for Patients With Advanced or Metastatic HER2 Breast Cancer
Sponsor:
Seagen Inc
Organization:
Seagen Inc
Conditions & Keywords Data
Conditions:
| Name |
|---|
| HER2-positive Breast Cancer |
Keywords:
| Name | View |
|---|---|
| Seattle Genetics | View |